Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congress has faith in Pfizer

Executive Summary

Pfizer was the pharmaceutical sector stock most widely held by members of the House and Senate in 2005 and the second-most widely held stock overall by Congress, according to the Center for Responsive Politics. Pfizer's stock dropped nearly 15% in 2005 (1"The Pink Sheet" Jan. 30, 2006, p. 27). The review found 32 Democrats and 47 Republicans held shares in Pfizer. Other widely held pharma sector stocks include Johnson & Johnson (number 7 overall), Procter & Gamble (8), Merck (16) and Amgen (18)...

You may also be interested in...



Pfizer’s Product Parachute? Firm Could See Rally Around New Approvals

Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO

The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel